keto phenol | 825632-57-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: keto phenol
• 英文别名: Hydroxycyclohexadienone；2-hydroxycyclohexa-2,4-dien-1-one
• CAS: 825632-57-3
• 化学式: C₆H₆O₂
• 分子量: 110.112
• InChiKey: XRXABBVBSHNVMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  三甲硅氧基-2-呋喃 在 cerium (IV) ammonium nitrate 作用下， 以 二氯甲烷 、 水 、 乙腈 为溶剂， 以58%的产率得到keto phenol
  参考文献：
  名称：

  Pyranoquinones with anticoccidial activity

  摘要：

  一种新的吡喃喹酮及其作为抗球虫药物的用途。

  公开号：

  US04965267A1

文献信息

• [EN] BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING HISTONE METHYLTRANSFERASE<br/>[FR] COMPOSÉ BICYCLIQUE ET SON UTILISATION POUR INHIBER L'HISTONE MÉTHYLTRANSFÉRASE
  申请人：ONCOTHERAPY SCIENCE INC

  公开号：WO2018165112A1

  公开（公告）日：2018-09-13

  The present invention relates to a compound represented by formula (I), a method for the preparation thereof, and a pharmaceutical composition containing the compound as an active ingredient for inhibiting histone methyltransferase such as SUV39H2.

  本发明涉及一种由式（I）表示的化合物，其制备方法，以及含有该化合物作为活性成分的药物组合物，用于抑制组蛋白甲基转移酶，如SUV39H2。
• [EN] POLYCYCLIC GLYOXYLATES AS PHOTOINITIATORS<br/>[FR] GLYOXYLATES POLYCYCLIQUES UTILISÉS EN TANT QUE PHOTO-INITIATEURS
  申请人：IGM GROUP B V

  公开号：WO2018041935A1

  公开（公告）日：2018-03-08

  The present invention relates to photoinitiator compounds of the formula (1) wherein X is O, S or a direct bond; Y is O, S or CR9R10; R1, R2, R3, R4, R5, R6, R7 and R8 independently of each other are hydrogen, halogen, C1- C18alkyl, C5-C10cycloalkyl, C2-C18alkenyl, phenyl, C1-C4alkoxy, C5-C7cycloalkoxy, phenoxy, C1-C4-alkylthio, C5-C7cycloalkylthio, phenylthio, di(C1-C4alkyl)amino, di(C5-C7cycloalkyl)amino, N-morpholinyl, N-piperidinyl or a group of formula (2) provided that one or more than one of R1, R2, R3, R4, R5, R6, R7 or R8 is a group of formula (2); R9, R10 independently of each other are hydrogen, C1-C18alkyl, C2-C12alkenyl, C5-C10cycloalkyl, phenyl-C1-C4alkyl, phenyl or together with the C atom to which they are attached form a 5-membered, 6-membered or 7-membered ring; and R11 is hydrogen, C1-C18alkyl, C5-C10cycloalkyl, C2-C12alkenyl, phenyl-C1-C4alkyl or phenyl.

  本发明涉及式（1）的光引发剂化合物，其中X为O、S或直接键；Y为O、S或CR9R10；R1、R2、R3、R4、R5、R6、R7和R8彼此独立地为氢、卤素、C1-C18烷基、C5-C10环烷基、C2-C18烯基、苯基、C1-C4烷氧基、C5-C7环烷氧基、苯氧基、C1-C4烷硫基、C5-C7环烷硫基、苯硫基、二(C1-C4烷基)氨基、二(C5-C7环烷基)氨基、N-吗啉基、N-哌啶基或式（2）的基团，前提是R1、R2、R3、R4、R5、R6、R7或R8中的一个或多个是式（2）的基团；R9、R10彼此独立地为氢、C1-C18烷基、C2-C12烯基、C5-C10环烷基、苯基-C1-C4烷基、苯基或与它们连接的碳原子一起形成5、6或7元环；R11为氢、C1-C18烷基、C5-C10环烷基、C2-C12烯基、苯基-C1-C4烷基或苯基。
• [EN] LATENT ACIDS AND THEIR USE<br/>[FR] ACIDES LATENTS ET LEUR UTILISATION
  申请人：BASF SE

  公开号：WO2011104127A1

  公开（公告）日：2011-09-01

  The invention pertains to a compound generating an acid of the formula (I) or (II), for instance corresponding sulfonium and iodonium salts, as well as corresponding sulfonyloximes, Formula (I) and Formula (II), wherein X is CH2 or CO; Y is O, NR4, S, O(CO), O(CO)O, O(CO)NR4, OSO2, O(CS), or O(CS)NR4; R1 is for example C1-C18alkyl, C1-C10haloalkyl, C2-C12alkenyl, C4-C30cycloalkenyl, phenyl-C1-C3-alkyl, C3-C30cycloalkyl, C3-C30cycloalkyl-C1-C18alkyl, interrupted C2-C18alkyl, interrupted C3-C30cycloalkyl, interrupted C3-C30cycloalkyl-C1-C18alkyl, interrupted C4-C30cycloalkenyl, phenyl, naphthyl, anthracyl, phenanthryl, biphenylyl, fluorenyl or heteroaryl, all unsubstituted or are substituted; or R1 is NR12R13; R2 and R3 are for example C3-C30cycloalkylene, C3-C30cycloalkyl-C1-C18alkylene, C1-C18alkylene, C1-C10haloalkylene, C2-C12alkenylene, C4-C30cycloalkenylene, phenylene, naphthylene, anthracylene, phenanthrylene, biphenylene or heteroarylene; all unsubstituted or substituted; R4 is for example C3-C30cycloalkyl, C3-C30cycloalkyl-C1-C18alkyl, C1-C18alkyl, C1-C10haloalkyl, C2-C12alkenyl, C4-C30cycloalkenyl, phenyl-C1-C3-alkyl; R12 and R13 are for example C3-C30cycloalkyl, C3-C30cycloalkyl-C1-C18alkyl, C1-C18alkyl, C1-C10haloalkyl, C2-C12alkenyl, C4-C30cycloalkenyl, phenyl-C1-C3-alkyl, Ar, (CO)R15, (CO)OR15 or SO2R15; and Ar is phenyl, biphenylyl, fluorenyl, naphthyl, anthracyl, phenanthryl or heteroaryl, all unsubstituted or substituted.

  该发明涉及一种生成式(I)或(II)的酸的化合物，例如相应的砜和碘砜盐，以及相应的砜酮肟，式(I)和式(II)，其中X为CH2或CO；Y为O、NR4、S、O(CO)、O(CO)O、O(CO)NR4、OSO2、O(CS)或O(CS)NR4；R1例如为C1-C18烷基、C1-C10卤代烷基、C2-C12烯基、C4-C30环烯烃基、苯基-C1-C3-烷基、C3-C30环烷基、C3-C30环烷基-C1-C18烷基、中断的C2-C18烷基、中断的C3-C30环烷基、中断的C3-C30环烷基-C1-C18烷基、中断的C4-C30环烯烃基、苯基、萘基、蒽基、菲基、联苯基、芴基或杂环烯基，全部为未取代或取代；或R1为NR12R13；R2和R3例如为C3-C30环烷基、C3-C30环烷基-C1-C18烷基、C1-C18烷基、C1-C10卤代烷基、C2-C12烯基、C4-C30环烯烃基、苯基、萘基、蒽基、菲基、联苯基或杂环烯基；全部为未取代或取代；R4例如为C3-C30环烷基、C3-C30环烷基-C1-C18烷基、C1-C18烷基、C1-C10卤代烷基、C2-C12烯基、C4-C30环烯烃基、苯基-C1-C3-烷基；R12和R13例如为C3-C30环烷基、C3-C30环烷基-C1-C18烷基、C1-C18烷基、C1-C10卤代烷基、C2-C12烯基、C4-C30环烯烃基、苯基-C1-C3-烷基、Ar、(CO)R15、(CO)OR15或SO2R15；Ar为苯基、联苯基、芴基、萘基、蒽基、菲基或杂环烯基，全部为未取代或取代。
• Heteroaryl fused azapolycyclic compounds
  申请人：Allen P. Martin

  公开号：US20050020830A1

  公开（公告）日：2005-01-27

  The present invention provides a compound having the structure of formula I: wherein R 1 is hydrogen, (C 1 -C 6 ) alkyl, unconjugated (C 3 -C 6 ) alkenyl, benzyl, YC(═O)(C 1 -C 6 ) alkyl or —CH 2 CH 2 —O—(C 1 -C 4 ) alkyl; X is CH 2 or CH 2 CH 2 ; Y is (C 2 -C 6 ) alkylene; Z is (CH 2 ) m , CF 2 , or C(═O), where m is 0, 1 or 2; R 2 and R 3 are selected independently from hydrogen, halogen, —(C 1 -C 6 ) alkyl optionally substituted with from 1 to 7 halogen atoms, and —O(C 1 -C 6 ) alkyl optionally substituted with from 1 to 7 halogen atoms, or R 2 and R 3 each together with the atom to which it is connected independently form C(═O), S→O, S(═O) 2 , or N→O; and is a 5- to 7-membered monocyclic heteroaryl group selected from pyridinyl, pyridone, pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, cinnolinyl, triazinyl, oxadiazolyl, thiadiazolyl and furazanyl groups.

  本发明提供了一种具有以下结构的化合物：其中R1为氢、(C1-C6)烷基、非共轭(C3-C6)烯基、苄基、YC(═O)(C1-C6)烷基或— —O—(C1-C4)烷基；X为CH2或 ；Y为(C2-C6)亚烯基；Z为( )m、CF2或C(═O)，其中m为0、1或2；R2和R3分别选择自氢、卤素、—(C1-C6)烷基（可选地取代1至7个卤素原子）、和—O(C1-C6)烷基（可选地取代1至7个卤素原子），或者R2和R3每个与其连接的原子独立地形成C(═O)、S→O、S(═O)2或N→O；和为从吡啶基、吡啶酮基、吡啶嗪基、咪唑基、嘧啶基、吡唑基、三唑基、吡嗪基、呋喃基、噻吩基、异噁唑基、噁唑基、异硫咪唑基、吡咯基、喹啉基、三嗪基、噁二唑基、噻二唑基和呋喃基组成的5-至7-环单环杂芳基。
• [EN] 4-(1-(SULFONYL)-1H-INDOL-2-YL)-4-(HYDROXY)-CYCLOHEXA-2,5-DIENONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS<br/>[FR] COMPOSES DE 4-(1-(SULFONYL)-1H-INDOL-2-YL)-4-(HYDROXY)-CYCLOHEXA-2,5-DIENONE ET ANALOGUES DE CEUX-CI UTILISES COMME AGENTS THERAPEUTIQUES
  申请人：CANCER REC TECH LTD

  公开号：WO2004056361A1

  公开（公告）日：2004-07-08

  This invention pertains to certain 4-(1-(sulfonyl)-1H-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds, and analogs thereof, including compounds of the following formula, which are, inter alia, antiproliferative agents, anticancer agents, and/or thioredoxin/thioredoxin reductase inhibitors: formula (I) wherein: Ar is a 1-(sulfonyl)-1H-indol-2-yl group; the bond marked alpha is independently: (a) a single bond; or: (b) a double bond; the bond marked beta is independently: (a) a single bond; or: (b) a double bond; the group -OR is independently: (a) -OH; (b) an ether group (e.g., -OMe); or: (c) an acyloxy (i.e., reverse ester) group (e.g., -OC(=O)Me); each of R<2>, R<3>, R<5>, and R<6>, is independently a ring substituent and is: (a) H; (b) a monovalent monodentate substituent; or: (c) a ring substituent which, together with an adjacent ring substituent, and together with the ring atoms to which these ring substituents are attached, form a fused ring; and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, for example, in the treatment of proliferative conditions, (e.g., cancer), and/or conditions mediated by thioredoxin/thioredoxin reductase.

  本发明涉及某些4-(1-(磺酰基)-1H-吲哚-2-基)-4-(羟基)-环己-2,5-二酮化合物及其类似物，包括以下式的化合物，其中这些化合物是抗增殖剂、抗癌剂和/或硫代雷帕敏/硫代雷帕敏还原酶抑制剂：式(I)其中：Ar是1-(磺酰基)-1H-吲哚-2-基；标记为α的键独立地是：(a) 单键；或：(b) 双键；标记为β的键独立地是：(a) 单键；或：(b) 双键；-OR基独立地是：(a) -OH；(b) 一个醚基团（例如，-OMe）；或：(c) 一个酰氧基（即，反酯基）（例如，-OC(=O)Me）；R2、R3、R5和R6中的每一个独立地是一个环取代基，可以是：(a) H；(b) 一价单齿取代基；或：(c) 一个环取代基，与相邻的环取代基一起，以及与这些环取代基连接的环原子一起形成融合环；以及其药学上可接受的盐、酯、酰胺、溶剂合物、水合物和受保护形式。本发明还涉及含有这些化合物的药物组合物，以及这些化合物和组合物的用途，无论是在体外还是体内，例如，在治疗增殖性疾病（例如，癌症）和/或由硫代雷帕敏/硫代雷帕敏还原酶介导的疾病方面。